key: cord-0697861-80xeibjz
authors: Leonardi, Andrea; Fauquert, Jean L.; Doan, Serge; Delgado, Luis; Andant, Nicolas; Klimek, Ludger; Bozkurt, Banu
title: Managing ocular allergy in the time of COVID‐19
date: 2020-05-25
journal: Allergy
DOI: 10.1111/all.14361
sha: 2c21bf6748a87bcfaf7a2aadef8768fc19d46b8a
doc_id: 697861
cord_uid: 80xeibjz

This spring, the majority of allergic patients are confined to their homes due to COVID-19 pandemic restrictions. In the following weeks, these restrictions will be reduced andpeople will be allowed to take walks, go jogging, and return to work.Spring is the time for ocular allergy (OA) to emerge with signs and symptoms consequent to increasing pollen counts. Even when wearing a mask, the eyes may remain unprotectedleading to an increase in ocular symptoms and patients seeking treatment forOA. However, access to routine consultation may remain problematic for many patients.

most common forms of OA such as seasonal and perennial allergic conjunctivitis (SAC and PAC). The management of severe forms such as vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC), which can result in corneal complications and cause sight-threatening sequelae, requires specialized expertise. 1 VKC and AKC may require repeated courses of topical corticosteroids and/ or long-term use of topical immunomodulators. Immunosuppression, even localized to the ocular surface through the topical use of cyclosporine and tacrolimus, has the potential to increase susceptibility, persistence, and reactivation of any viral infection. Although the presence of SARS-CoV-2 in tears has rarely been detected in infected individuals, 2,3 conjunctivitis may be a sign of COVID-19, prior to or after the onset of respiratory symptoms. 4 Recommendations on the management of OA were recently published by the EAACI working group on OA (WG-OA). 5 Considering the numerous problems due to the COVID-19 pandemic, including the health system crisis and limited access to consultants, we were Regarding VKC/AKC, topical antiallergic drugs remain definitively the first-choice treatment, with the addition of topical corticosteroids as the second-choice treatment ( Table 2) . Regarding patients with current infection, there is disagreement on the choice of topical corticosteroid regimen; 57% of the respondents will use them as pulse therapy, while 14% a slow dose for long term ( 

Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface

Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection

Assessing viral shedding and infectivity of tears

Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease

Management of ocular allergy

A randomized, controlled trial of cyclosporine A Cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study

Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study

Allergic eye disease in children and adolescents seeking eye care in India: electronic medical records driven big data analytics report II

Prevalence of vernal keratoconjunctivitis and its associated factors among children in Gambella town, southwest Ethiopia